Level 9, Suite 1, 68 Pitt Street,
Sydney, NSW, 2000, Australia

+61 (02) 8964 7401

Social Media

Xanamem™ Pipeline

Xanamem™ Pipeline

Xanamem™’s novel mechanism of action – blocking excess cortisol production – means that the clinical product pipeline offers a number of additional indications in the central nervous and endocrine/metabolic systems. Potential development opportunities include:

  • Diabetes – Cognitive dysfunction
Actinogen Medical Market Focus

This information is closely related to our Other Indications information.

Subscribe to our newsletter

Are you an Investor?  Yes